PAS
ITOS

Point72 Asia (Singapore)’s iTeos Therapeutics ITOS Stock Holding History

Point72 Asia (Singapore)’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1
Closed -$6 – 1076
2025
Q1 		$6 Sell
1
-5,426
-100% -$39.8K ﹤0.01% 827
2024
Q4 		$41.7K Buy
+5,427
New +$46.6K 0.01% 541
2024
Q2 		– Sell
-1,373
Closed -$18.7K – 1258
2024
Q1 		$18.7K Sell
1,373
-233
-15% -$2.54K ﹤0.01% 969
2023
Q4 		$17.6K Buy
+1,606
New +$15.9K ﹤0.01% 468

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asia (Singapore)'s ITOS Position: Q2 2025 in Review

Point72 Asia (Singapore) sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 1 share — an estimated $6 sold.

Point72 Asia (Singapore) first reported a position in ITOS in Q4 2023 and held it in 4 quarters. The position peaked at $41.7K in Q4 2024. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • Point72 Asia (Singapore) reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 1 iTeos Therapeutics share in Q2 2025, an estimated $6.
  • Point72 Asia (Singapore) first reported a position in iTeos Therapeutics in Q4 2023 and held it in 4 quarters.
  • Point72 Asia (Singapore)'s iTeos Therapeutics position peaked at $41.7K in Q4 2024.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q2 2025, filed 14 Aug 2025.